Literature DB >> 27373843

Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.

Maurício Dos-Santos-Pereira1, Célia Aparecida da-Silva2, Francisco Silveira Guimarães3, Elaine Del-Bel4.   

Abstract

Entities:  

Keywords:  AIMs; Anandamide; CB1; COX-2; Cannabinoid; ERK 1/2; LID; NF-κB; Neuroinflammation; PPAR gamma; TRPV-1; pAcH3

Mesh：

Substances：

Year:  2016        PMID： 27373843     DOI： 10.1016/j.nbd.2016.06.013

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN： 0969-9961            Impact factor:   5.996


× No keyword cloud information.
  23 in total

Review 1.  Nanomedicine to Overcome Current Parkinson's Treatment Liabilities: A Systematic Review.

Authors:  Gabriel Henrique Hawthorne; Marcelo Picinin Bernuci; Mariza Bortolanza; Vitor Tumas; Ana Carolina Issy; Elaine Del-Bel
Journal:  Neurotox Res       Date:  2016-08-31       Impact factor: 3.911

2.  Bi-directional modulation of food habit expression by the endocannabinoid system.

Authors:  Carol A Gianessi; Stephanie M Groman; Jane R Taylor
Journal:  Eur J Neurosci       Date:  2019-01-11       Impact factor: 3.386

Review 3.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

Review 4.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

Review 5.  Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Authors:  José Alexandre S Crippa; Jaime E C Hallak; Antônio W Zuardi; Francisco S Guimarães; Vitor Tumas; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-31       Impact factor: 5.270

Review 6.  Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review.

Authors:  Premalatha Balachandran; Mahmoud Elsohly; Kevin P Hill
Journal:  J Gen Intern Med       Date:  2021-01-29       Impact factor: 6.473

7.  Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats.

Authors:  Fernanda F Peres; Raquel Levin; Mayra A Suiama; Mariana C Diana; Douglas A Gouvêa; Valéria Almeida; Camila M Santos; Lisandro Lungato; Antônio W Zuardi; Jaime E C Hallak; José A Crippa; D'Almeida Vânia; Regina H Silva; Vanessa C Abílio
Journal:  Front Pharmacol       Date:  2016-09-28       Impact factor: 5.810

8.  Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study.

Authors:  Maureen A Leehey; Ying Liu; Felecia Hart; Christen Epstein; Mary Cook; Stefan Sillau; Jost Klawitter; Heike Newman; Cristina Sempio; Lisa Forman; Lauren Seeberger; Olga Klepitskaya; Zachrey Baud; Jacquelyn Bainbridge
Journal:  Cannabis Cannabinoid Res       Date:  2020-12-15

9.  Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats.

Authors:  Chang-Qing Zheng; Hong-Xia Fan; Xiao-Xian Li; Jing-Jie Li; Shuo Sheng; Feng Zhang
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

Review 10.  Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Authors:  Fernanda F Peres; Alvaro C Lima; Jaime E C Hallak; José A Crippa; Regina H Silva; Vanessa C Abílio
Journal:  Front Pharmacol       Date:  2018-05-11       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.